RxSight preliminary Q1 revenue $37.9M (+28% YoY); cuts FY2025 guidance to $160M-$175M

RxSight, Inc.

2025-Q1 EPS reported -$0.20 revenue$37,895,000

Preliminary Q1 2025 revenue ~$37.9M, up 28% YoY but down 6% QoQ; LAL procedure volume 27,579 (+36% YoY).
LDD installed base reached 1,044 as of March 31, 2025, a 43% increase from 732 a year earlier.
FY2025 revenue guidance lowered to $160M-$175M (from $185M-$197M); operating expense guidance cut to $150M-$160M.
Stock-based compensation expected to be $27M-$30M, up from prior $22M-$25M; cites premium IOL market headwinds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.